SK1142001A3 - Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them - Google Patents

Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them Download PDF

Info

Publication number
SK1142001A3
SK1142001A3 SK114-2001A SK1142001A SK1142001A3 SK 1142001 A3 SK1142001 A3 SK 1142001A3 SK 1142001 A SK1142001 A SK 1142001A SK 1142001 A3 SK1142001 A3 SK 1142001A3
Authority
SK
Slovakia
Prior art keywords
formula
compound
group
piperazine derivative
piperazine
Prior art date
Application number
SK114-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Gerard Moinet
Dominique Marais
Didier Mesangeau
Liliane Doare
Micheline Kergoat
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK1142001A3 publication Critical patent/SK1142001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
SK114-2001A 1998-07-28 1999-07-17 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them SK1142001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9809660A FR2781797B1 (fr) 1998-07-28 1998-07-28 Derives de piperazine antidiabetiques, leurs procedes de preparation et compositions pharmaceutiques les contenant
PCT/EP1999/005111 WO2000006558A1 (fr) 1998-07-28 1999-07-17 Derives antidiabetiques de piperazine, leurs procedes de preparation et compositions les contenant

Publications (1)

Publication Number Publication Date
SK1142001A3 true SK1142001A3 (en) 2001-09-11

Family

ID=9529125

Family Applications (1)

Application Number Title Priority Date Filing Date
SK114-2001A SK1142001A3 (en) 1998-07-28 1999-07-17 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them

Country Status (17)

Country Link
US (1) US6376495B1 (fr)
EP (1) EP1100790A1 (fr)
JP (1) JP2002521477A (fr)
KR (1) KR20010072775A (fr)
AR (1) AR020646A1 (fr)
AU (1) AU752993B2 (fr)
BR (1) BR9913149A (fr)
CA (1) CA2338694A1 (fr)
FR (1) FR2781797B1 (fr)
HU (1) HUP0102830A3 (fr)
NO (1) NO20010469L (fr)
PL (1) PL345735A1 (fr)
RU (1) RU2208610C2 (fr)
SK (1) SK1142001A3 (fr)
TW (1) TW472046B (fr)
WO (1) WO2000006558A1 (fr)
ZA (1) ZA200102495B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372715A1 (fr) * 1999-05-13 2001-04-12 Shionogi & Co., Ltd. Principes actifs destines au soin ou a la prevention de diabetes
FR2829765A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
AU2006282403B2 (en) 2005-08-26 2011-07-07 Institute Of Medicinal Molecular Design, Inc. Derivative having PPAR agonistic activity
JP2008239616A (ja) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Ｈｄｌ上昇剤
CN102485717B (zh) 2010-12-06 2015-12-02 中国人民解放军军事医学科学院毒物药物研究所 噻唑胺衍生物及其作为抗小rna病毒感染药物的用途
FR2976943B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2976942B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2999427B1 (fr) 2012-12-17 2015-01-30 Metabolys Composition et kit comprenant des derives de piperazine et de la metformine, leur utilisation dans le traitement du diabete

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3277094A (en) * 1965-05-10 1966-10-04 Ciba Geigy Corp Piperazine derivatives
US3951983A (en) * 1970-11-10 1976-04-20 Pfizer Inc. Phenoxypropanolpiperazines
DE3564683D1 (en) * 1984-08-07 1988-10-06 Cortial 4-(arylpiperazinylethylaminoethoxy) phenol derivatives, process for their preparation and their therapeutical application
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists

Also Published As

Publication number Publication date
RU2208610C2 (ru) 2003-07-20
NO20010469D0 (no) 2001-01-26
CA2338694A1 (fr) 2000-02-10
PL345735A1 (en) 2002-01-02
NO20010469L (no) 2001-01-26
HUP0102830A3 (en) 2002-12-28
US6376495B1 (en) 2002-04-23
FR2781797B1 (fr) 2000-11-03
AU752993B2 (en) 2002-10-03
EP1100790A1 (fr) 2001-05-23
HUP0102830A2 (hu) 2001-12-28
ZA200102495B (en) 2002-09-27
WO2000006558A1 (fr) 2000-02-10
BR9913149A (pt) 2003-01-21
KR20010072775A (ko) 2001-07-31
AU5160999A (en) 2000-02-21
AR020646A1 (es) 2002-05-22
FR2781797A1 (fr) 2000-02-04
JP2002521477A (ja) 2002-07-16
TW472046B (en) 2002-01-11

Similar Documents

Publication Publication Date Title
US5206366A (en) Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
WO2008154484A1 (fr) Inhibiteurs d'ire-1a
JP6752283B2 (ja) Ｅｇｆｒキナーゼ阻害剤およびその製造方法と使用
IL170093A (en) Method for preparing acid addition salts of polyacidic basic compounds
CZ397598A3 (cs) Derivát 5-fenoxyalkyl-2,4-thiazolidindionu, způsob jeho přípravy, meziprodukty pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
US6380229B1 (en) 2-(N-cyanoimino)thiazolidin-4-one derivatives
PL95166B1 (fr)
SK1142001A3 (en) Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them
US4305944A (en) N-[(4-[3-cyano substituted pyridyl]piperazino)alkyl]-azaspirodecanediones
IE912492A1 (en) 1,4-disubstituted piperazines
WO2012098501A1 (fr) Co-cristaux de fébuxostat
SU1340585A3 (ru) Способ получени производных тетразола
NL8002071A (nl) 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)- benzoee- zuurderivaten, werkwijze voor de bereiding daarvan, alsmede farmaceutische preparaten die deze bevatten.
KR101919642B1 (ko) 피페라진 유도체, 이를 제조하는 방법, 및 인슐린 저항성의 치료에서 이의 용도
CZ2001301A3 (cs) Antidiabetický derivát piperazinu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje
JPS5838277A (ja) スピロチアゾリジニルピペラジン誘導体
JPS6044307B2 (ja) 新規のｏ−アルキル化オキシムおよび医薬としてのその用途
PL164152B1 (pl) Sposób wytwarzania nowych pochodnych 2-iminobenzotiazoliny PL
AU2012273969A1 (en) Piperazine derivatives, methods for preparing same, and uses thereof in the treatment of insulin resistance
CZ135193A3 (en) Derivatives of 2 amino-n-{/£4-(aminocarbonyl)pyrimidin-2-yl|amino/alkyl} pyrimidine-4-carboxamide, process of their preparation and pharmaceutical preparations in which they are comprised
MXPA01000979A (en) Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them
PL97545B1 (pl) Sposob wytwarzania nowych pochodnych oksazolidyny
JPH0525115A (ja) アミド化合物およびその合成中間体
CZ118893A3 (en) Novel nitriles of 1-aryl-4-piperazinylcyckohexanecarboxylic acids, their preparation and use